Skip to main content
. 2018 Dec 18;8:435. doi: 10.3389/fcimb.2018.00435

Figure 2.

Figure 2

In vitro glycosylation assays. (A) 100066N, 102644N, and 104108N structures. (B) Western blot analysis of the inhibition of NleB1 and SseK1 glycosylation of GAPDH by 100066N and 102644N. (C) Quantification of panel B, n = 3. (D) UDP-Glo assays were performed using 250 nM NleB1, in 125 mM Tris pH 7.4, 25 mM MnCl2, 2.5 mM DTT, and 100 μM UDP-GlcNAc in the presence of inhibitor concentrations ranging from 1 nM to 500 μM. (E) Western blot analysis of the inhibition of SseK2 glycosylation of FADD by 100066N and 102644N.